Detalles de la búsqueda
1.
Health resource utilisation associated with skeletal-related events in patients with bone metastases secondary to solid tumours: regional comparisons in an observational study.
Eur J Cancer Care (Engl)
; 26(6)2017 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-26865392
2.
Cost-Effectiveness Analysis of Panitumumab Plus Mfolfox6 Versus Bevacizumab Plus Mfolfox6 for First-Line Treatment of Patients with Wild-Type Ras Metastatic Colorectal Cancer.
Value Health
; 17(7): A632, 2014 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-27202247
3.
Cost of skeletal complications from bone metastases in six European countries.
J Med Econ
; 19(6): 611-8, 2016 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-26849381
4.
Prevalence of RAS mutations and individual variation patterns among patients with metastatic colorectal cancer: A pooled analysis of randomised controlled trials.
Eur J Cancer
; 51(13): 1704-13, 2015 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-26049686
5.
Health resource utilization associated with skeletal-related events in patients with bone metastases: Results from a multinational retrospective - prospective observational study - a cohort from 4 European countries.
J Bone Oncol
; 3(2): 40-8, 2014 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-26909296
6.
Cost of skeletal-related events in European patients with solid tumours and bone metastases: data from a prospective multinational observational study.
J Med Econ
; 16(5): 691-700, 2013.
Artículo
en Inglés
| MEDLINE | ID: mdl-23441975
Resultados
1 -
6
de 6
1
Próxima >
>>